Literature search strategy.

We searched for literature from January 2017 through January 2021 in MEDLINE and Science Citation Index Expanded, to append new articles to the prior search done with the same search terms but a timeframe of 2010 through 2016. These searches resulted in 34 and 245 new articles found, respectively, with 11 unique abstracts retained for further review. (DOCX)</p

Estimated proportion of people who inject drugs, men who have sex with men, and trans women estimated to have been treated and cured of hepatitis C virus infection each year in San Francisco, 2015–2019.

Estimated proportion of people who inject drugs, men who have sex with men, and trans women estimated to have been treated and cured of hepatitis C virus infection each year in San Francisco, 2015–2019.</p

Estimated population size and number of people with anti-HCV seropositivity, acute infection, chronic infection, and active infection after adjusting for treatment, 2019.

Estimated population size and number of people with anti-HCV seropositivity, acute infection, chronic infection, and active infection after adjusting for treatment, 2019.</p

Summary of Estimated HCV Burden by Subpopulation, 2019.

This table demonstrates the percentage of total infections borne by each subpopulation; this helps to illustrate HCV health disparities among subpopulations. For example, 73.1% of all people with anti-HCV antibodies in San Francisco in 2019 were PWID, though only an estimated 2.8% of San Francisco residents overall are PWID. Note that the rows are not exclusive (i.e., some are by risk group, some by age, and some by sex) and therefore the final three columns do not total to 100%.</p

Abstracts retained for further review after literature search.

Eleven unique abstracts were retained for further review after following the literature search methods described in S1 Table. These abstracts are listed below. (DOCX)</p

Summary of data sources.

The table below summarizes the main sources of data for each population size and HCV prevalence estimate contained in this analysis. (DOCX)</p

Antigen’s description.

Antigen’s description.</p

Relationship between observed and predicted logarithm of the proviral load.

(A) HTLV-1 samples (N = 246) were plotted by their observed log (PVL) and predicted log (PVL). The linear curve x = y represents the estimated perfect correlation. (B) HTLV-2 samples (N = 245) were plotted by their observed log (PVL) and predicted log (PVL). The linear curve x = y represents the estimated perfect correlation.</p

Examples of serological patterns obtained with Multi-HTLV.

(A) Examples for three negative blood donors. These are either non-reactive samples or samples that show cross-reactivity with isolated GP46 confirmatory and/or GP46-II typing antigens. (B) Examples for three HTLV-1 patients. Different profiles were observed depending on the individual immune response of each patient. (C) Examples for three HTLV-2 patients. Different profiles were observed depending on the individual immune response of each patient.</p

Examples of serological profiles of 3 different patients followed-up overtime.

(A) Antigen reactivities obtained with Multi-HTLV and INNO-LIA assays for one HTLV-1 & two HTLV-2 patients. (B) Plots showing comparative evolution of proviral load and the sum of 6 antigens intensities measured by Multi-HTLV for one HTLV-1 and two HTLV-2 patients over 10–11 years. (PDF)</p